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Background/aim: Bevacizumab is a chemotherapeutic drug, which selectively binds to vascular endothelial growth factor (VEGF)
and mainly inhibits angiogenesis and neovascularization. We aimed to study the possible effects of bevacizumab on right ventricular
pressure (RVP), right ventricular hypertrophy, and VEGF, in hypoxia - induced pulmonary hypertension (PH) rat model.
Materials and methods: 24 adult Wistar Albino rats were randomly divided into four groups: control group - saline; Bevacizumab
Group; PH Group; PH + Bevacizumab Group. In hypoxia - induced model, 10% oxygen and 90% nitrogen were applied in a plexiglas
box for eight days to PH Group and PH + Bevacizumab Group. On day eight, RVPs were measured directly from the heart, and then
animals were sacrificed. Heart and lung tissues were examined, and Fulton index was measured.
Results: RVP, Fulton index, and tissue VEGF scores were significantly lower in PH + Bevacizumab group than PH group: median
(ranges), RVP, mmHg, 37.8 (33.0–39.0) and 32.3 (28.0–35.0), p: 0.01; Fulton index: 0.30 (0.29–0.33) and 0.25 (0.24–0.26), p: 0.003; tissue
VEGF scores: 5.1 (4.8–5.3) and 4.0 (3.8 4.1), p: 0.004, respectively.
Conclusion: Bevacizumab, which is indeed an antineoplastic agent, might have a favorable effect on hypoxia - induced pulmonary
hypertension.
Key words: Hypertension, pulmonary, bevacizumab, hypoxia

1. Introduction
Pulmonary hypertension (PH) is a clinical disorder that
may complicate cardiovascular and respiratory diseases
[1]. PH is defined as an increase in mean pulmonary
arterial pressure (PAPm) ⩾ 25 mmHg at rest measured
during right heart catheterization [2] in humans.
The most important mechanisms in PH pathogenesis
revealed by scientific studies are as follows: 1. Endothelial
dysfunction leading to vasoconstriction and thrombosis,
2. Genetic mutations such as BMPR - 2 and EIF2AK4, 3.
Cancer - like cellular responses (increased proliferation,
impaired apoptosis and glycolytic metabolism in
pulmonary artery smooth muscle, fibroblasts, and
endothelial cells), 4. Rho - kinase activation and refractory

vasoconstriction, 5. Right ventricular (RV) failure (as a
result of increased afterload) [3].
Vascular endothelial growth factor (VEGF) is an
endothelial cell mitogen and angiogenic factor that
binds to endothelial cells via tyrosine kinase receptors
(two subtypes: VEGFR – 1 / KDR and VEGFR – 2 / Flt)
in the pulmonary circulation, which could be related
to cancer - like cellular responses. Both VEGF and its
receptors are upregulated in acute and chronic hypoxia
[4]. VEGF expression, VEGFR - 1 levels in pulmonary
endothelium, and VEGFR - 2 levels in plexiform lesions
are also increased [5,6]. In rat models, chronic VEGFR 2 blockade together with hypoxia may induce pulmonary
endothelial cell apoptosis. In some apoptosis - resistant cell
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groups, an increased proliferation may occur, which can
cause a severe form of PH [7].
Chronic hypoxia is one of the frequent causes of
PH. Its effects on the pulmonary vascular system have
been extensively studied in both in vitro and in vivo
experimental studies [8-10]. Acute hypoxia causes
reversible vasoconstriction in pulmonary arteries by
increasing endothelin - 1 (ET - 1), serotonin, hypoxia, and
redox - sensitive potassium channel activity in pulmonary
vascular smooth muscle cells [10]. Chronic hypoxia, on the
other hand, often causes irreversible effects and vascular
remodelling. However, the histopathological changes in
the chronic hypoxia animal model of PH are not totally
irreversible [11]. Despite these differences, the chronic
hypoxia animal model is frequently used in PH studies
due to its ease of application and the fact that it causes a
significant PH in animals.
Bevacizumab is a drug used in the treatment of some
cancers, mainly colon cancer. It is a recombinant humanized
monoclonal IgG1 antibody that selectively binds to VEGF
and neutralizes this mediator’s biological activity. It mainly
inhibits angiogenesis and neovascularisation and thus,
effectively controls cancer cells’ proliferation and prevents
metastases [12].
Due to VEGF’s inhibitory effect on angiogenesis,
we hypothesized that bevacizumab might affect PH
pathogenesis. Thus, we aimed to study the possible effects
of bevacizumab in hypoxia - induced PH animal model.
2. Materials and methods
2.1. Experimental design
Ethical approval for all the experimental procedures
was obtained from the Dokuz Eylül University Local
Ethics Committee for Animal Experiments (392009,
İzmir, Turkey). 24 adult male Wistar Albino rats between
200–250 mg were used in this study. Rats were randomly
divided into four groups, with six rats in each group.
During the experiment, they were housed in standard rat
cages and fed with standard rodent food. Relative humidity
was measured as 55% in the accommodation chambers.

The body weights of all rats included in the study were
weighed and recorded when starting the experiment. All
animals were fed ad libitum and exposed to the same
day-night cycle (circadian rhythm: 12 h dark, 12 h light).
Experimental groups were planned as: Group 1 (control
group - saline): As of day 0, rats breathe room air, and
0.9% saline was applied intraperitoneally (i.p.) on day 5.
Group 2 (Bevacizumab Group): As of day 0, rats breathe
room air, and 1 mg / kg bevacizumab was applied i.p. on
day 5. In the literature, doses of bevacizumab applied in
animal (rats) studies mainly ranged between 0.1 mg / kg
and 10 mg / kg [13,14]. We chose the dose of 1 mg / kg as
an average of this range. Group 3 (PH group): As of day 0,
rats breathe a mixture of 10% oxygen and 90% nitrogen in
a closed chamber, and 0.9% saline was applied i.p. on day
5. Group 4 (PH + Bevacizumab group): As of day 0, rats
breathe a mixture of 10% oxygen and 90% nitrogen in a
closed chamber, and 1 mg / kg bevacizumab was applied
i.p. on day 5. Animals in all groups were sacrificed on
day 8 after the necessary measurements were made. The
duration of follow up was determined as 8 days based on
our observations in the pilot study. Table summarizes the
experiment groups. Hypoxia-induced model used in the
experiments is a normobaric model and was carried out
by applying a gas mixture consisting of 10% oxygen and
90% nitrogen at a rate of 2 lt / min to a Plexiglas box with
dimensions of 110 × 56 × 35 cm and a total volume of 215
lt, for 23 h a day for eight days [15-20]. The Plexiglas box
was opened twice a day to clean the cages and for feeding
purposes, each lasting approximately 30 min [16–19].
The levels of oxygen, carbon dioxide, and nitrogen in the
Plexiglas box were measured and recorded three times
a day with an anaesthetic gas monitor (Anaesthetic Gas
Monitor Type 1304, Bruel & Kjaer). Necessary adjustments
have been applied to keep the oxygen level between
10%–15% and the carbon dioxide level < 0.2% in the box
environment. The average room temperature was between
22–24 °C. Soda-lime was sprinkled on the box’s basement
to bind the box environment’s excess carbon dioxide and
humidity [16,17,19,20]. Soda-lime material was changed
daily.

Table. Description of the experiment groups.
Group

Description

Group 1 (Control Group - Saline)

Breathe room air, 0.9% saline i.p. applied on day 5

Group 2 (Bevacizumab Group)

Breathe room air, 1 mg / kg bevacizumab i.p. applied on day 5

Group 3 (PH group)

Breathe a mixture of 10% oxygen and 90% nitrogen in a closed chamber, 0.9% saline i.p.
applied on day 5

Group 4 (PH + Bevacizumab group)

Breathe a mixture of 10% oxygen and 90% nitrogen in a closed chamber, 1 mg / kg
bevacizumab i.p. applied on day 5
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2.2. Hemodynamic measurements
The animals were weighed, and their breathing patterns,
oral intakes, and heart rates were monitored daily. On Day
5, 0.9% saline i.p. was applied to Group 1 and 3, and 1 mg /
kg bevacizumab i.p. was applied to Group 2 and 4. On the
eighth day, all rats were anesthetized with a combination of
ketamine and xylazine (5 mg / kg xylazine i.p. and 35 mg
/ kg ketamine i.p.). Rats were fixed in the supine position.
Thoracic cavity was opened in all rats by thoracotomy and
right ventricular pressures (RVP) were measured directly
from the heart as described before [21]. Briefly, right
ventricular mean pressure (reflecting pulmonary artery
pressure) and left ventricular systolic pressure (reflecting
systemic arterial pressure) were recorded by using 20 G
catheters with pressure transducers continuously. Pressure
measurements were made from the right ventricle instead
of the pulmonary artery because pulmonary artery
catheterization is technically very difficult in rats with
pulmonary hypertension due to high pressures. Petaş
KMA 250 Pressure Transducer and Recording System was
used for measurements. After the pressure measurements
were completed, the animals were sacrificed by taking
their whole - body blood (approximately 5 mL for each
animal) via an intracardiac puncture, and the heart and
lungs of animals were dissected for further examinations.
2.3. Serum VEGF measurements
VEGF levels were measured in the serum by using
Invitrogen (CA_USA) Rt VEGF kit and solid-phase
sandwich Enzyme Linked - Immuno Sorbent Assay
(ELISA) method.
2.4. Morphometrical and pathological evaluation
Fulton Index (Right Ventricle / Left Ventricle + Septum
Weight Ratio) [22] was measured on heart tissues. Lungs
and hearts were fixed in 10% neutral buffered formalin for
at least 24 h. The fixed heart and lung tissues were processed
in the pathology laboratory within 24 h. Tissue samples
were routinely processed, embedded in paraffin, and cut
to 5µ sections. The histological sections were stained with
hematoxylin & eosin (H & E). In the H & E - stained
sections, the thickness of the muscularis mucosa layer
(Medial Thickness = MT) of 25 small pulmonary arteries
(diameter < 100 µm) was measured morphometrically
at × 40 magnification. Besides, the external diameter of
each vessel was measured [15,17,23,24]. Then, medial
thickness / external diameter (distance between external
elastic laminae) ratios were calculated, and each value was
multiplied by 100 to convert these values to percentage
values. Thus, medial thickness% (MT%) values were
obtained.
2.5. Immunohistochemistry
Sections from paraffin - embedded tissue blocks were
taken on lysine - coated slides. After deparaffinization and
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rehydration, slides were placed in a plastic jar filled with
phosphate - buffered saline (PBS, pH: 7.2). Endogenous
peroxidase activity was quenched with hydrogen peroxide.
The tissue sections were then incubated with polyclonal
antibody to VEGF (dilution: 1 / 200, ab46154_Abcam_
MA_USA). Primary antibodies were applied overnight
at 4 °C and washed in PBS. The binding of VEGF was
detected using the streptavidin - biotin immunoperoxidase
method. Diaminobenzidine was used as a chromogen. In
VEGF antibody - stained sections, 25 pulmonary arteries
were examined randomly at × 40 magnification, and
VEGF tissue score was used as staining criteria. Staining
intensity and staining percentages of each pulmonary
artery endothelium with VEGF antibody were used to
obtain this score. Staining intensity was scored as in the
following: No staining = 0, weak intensity of staining =
1, medium intensity of staining = 2, strong intensity of
staining = 3. Staining percentage was scored as: < 10%
staining = 1, 10 - 50% staining = 2, 50 - 90% staining = 3
and 100% staining = 4. VEGF tissue score of each vessel
was calculated by summing the staining intensity score and
the staining percentage scores [23,25]. Two pathologists
performed all these pathological procedures who did not
know which animal and which experimental group the
sections belonged to (blind study technique). Afterward,
the average of the morphometric measurements (MT and
MT%) and immunohistochemistry measurements (tissue
VEGF scores) of each animal were calculated, and these
values were used in statistical analysis.
2.6. Statistical analysis
Measurements of weight, RVP, Fulton İndex, MT,
and tissue VEGF scores were presented in the Results
Section as median and ranges and in the figures as mean
and standard deviations (SD). We applied hierarchical
comparisons based on hypoxia - induced PH modelling
as our primary hypothesis (between PH group and PH +
Bevacizumab group). Pair - wise comparisons in the nonPH and PH groups included control group - saline vs.
Bevacizumab group, and PH group vs. PH + Bevacizumab
group, respectively [26]. Accordingly, p value for pair
- wise comparisons was corrected by dividing 0.05 to
two, i.e. 0.025. For intergroup comparisons, Kruskal–
Wallis test followed by Mann–Whitney test with
Bonferroni correction was used. Friedman S test was
used for intragroup comparisons, and Wilcoxon test with
Bonferroni correction was used for pairwise comparisons.
For weight changes, intragroup comparisons were made
between D0 to D5, and D5 to D8. P values less than 0.05,
in the two - sided testing were accepted for statistical
significance. P values to define the statistical significance
for pair - wise comparisons, as outlined above were
depicted in the figure legends. SPSS, version 18.0 (PASW
Statistics, USA) was used in the statistical analysis.
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3. Results
3. 1. Weight measurements
Weight measurements of the groups from Day 0 to Day 5
and Day 5 to Day 8, were (median, and ranges) in grams
were as follows: control group - saline: 236, 216 to 240 –
239, 228 to 250 – 246, 228 to 250; Bevacizumab group: 216,
200 to 230 – 221, 204 to 245 – 230, 196 to 280; PH group:
253, 230 to 264 – 213, 176 to 225 – 200, 167 to 204; PH +
Bevacizumab group: 226, 209 to 245 – 184, 158 to 195 – 165,
158 to 190, respectively. Weight changes were significant in
the control group - saline from day 5 to day 8, p: 0.046; in
the PH group from day 0 to day 5, p: 0.027, and from day
5 to day 8, p: 0.028; and in the PH + Bevacizumab group
from day 0 to day 5, p: 0.028. Mean, and SD of the weight
measurements of the experiment groups, in day 0, day 5,
and day 8 were provided in Figure 1.
3.2. Right ventricular pressure (RVP)
RVP was significantly greater in the PH group than control
group - saline (p: 0.004), and PH + Bevacizumab group
(p: 0.01). Median and ranges in mmHg were control group
- saline: 11.0, 9.0 to 12.0; Bevacizumab group: 11.0, 10.0
to 12.0; PH group: 37.8, 33.0 to 39.0; PH + Bevacizumab
group: 32.3, 28.0 to 35.0; p < 0.001 for all groups’
comparison. RVP measurements of the experiment groups
are shown in Figure 2a.
3.3. Fulton index
Fulton index was significantly greater in the PH
Group than control group - saline (p: 0.003), and PH +
Bevacizumab group (p: 0.003). Median and ranges were
control group - saline: 0.21, 0.20 to 0.23; Bevacizumab
*p: 0.078

*p: 0.080
300

*p: 0.027

**p: 0.116

**p: 0.046

group: 0.21, 0.20 to 0.23; PH group: 0.30, 0.29 to 0.33; PH
+ Bevacizumab group: 0.25, 0.24 to 0.26; p < 0.001 for all
groups’ comparison. Fulton index measurements of the
experiment groups are shown in Figure 2b.
3.4. Serum VEGF levels
Serum VEGF level was not significantly different between
the groups. Median and ranges in pg / mL were control
group - saline: 56.9, 41.5 to 96.4; Bevacizumab Group:
65.5, 55.2 to 103.8; PH Group: 89.5, 52.8 to 134.2; PH
+ Bevacizumab Group: 83.9, 70.2 to 97.2; p: 0.14 for all
groups’ comparison. Serum VEGF levels of the experiment
groups are shown in Figure 3.
3.5. Medial thickness (MT)
MT was significantly greater in the PH Group than control
group - saline (p: 0.004), and PH + Bevacizumab Group
(p: 0. 01). Median and ranges in µm were control group saline: 15.5, 14.3 to 16.5; Bevacizumab Group: 15.3, 14.6
to 17.1; PH Group: 27.4, 26.0 to 28.3; PH + Bevacizumab
Group: 24.4, 24.1 to 27.2; p < 0.001 for all groups’
comparison. MT and MT% of the experiment groups are
shown in Figures 4a and 4b. Four different H & E - stained
sections of small pulmonary arteries are shown in Figures
5a–5d.
3.6. VEGF tissue score
VEGF tissue score was significantly greater in the PH
group than control group - saline (p: 0.004), and PH +
Bevacizumab group (p: 0.004). Median and ranges were
Control Group - saline: 3.9, 3.4 to 4.2; Bevacizumab group:
3.8, 3.5 to 4.2; PH Group: 5.1, 4.8 to 5.3; PH + Bevacizumab
group: 4.0, 3.8 to 4.1; p: 0.004 for all groups’ comparison.
*p: 0.028

**p: 0.028

**p: 0.080

250
200
150
100
50
0

D0

D5

D8

Control Group-Saline

D0

D5

D8

Bevacizumab Group

D0

D5

D8

PH Group

D0

D5

D8

PH + Bevacizumab
Group

Figure 1: Weight measurements of the experiment groups, in day 0, day 5, and day 8 (d0, d5, and d8, respectively): Weight changes were
significant in the control group - saline from d5 to d8, p: 0.046; in the ph group from d0 to d5, p: 0.027, and from d5 to d8, p: 0.028;
and in the PH + Bevacizumab group from d0 to d5, p: 0.028. Mean and SD of the measurements were provided in the figure. *: Weight
change from d0 to d5, **: weight change from D5 to D8.
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RVP, MmHg

* p: 0.004; ** p: 0.867; *** p: 0.011
45
a
40
35
30
25
20
15
10
5
0
Control Group-Saline

Bevacizumab Group

PH Group

PH + Bevacizumab

* p: 0.003; ** p: 0.490; *** p: 0.003
0.35

Fulton Index

0.30

b

0.25
0.20
0.15
0.10
0.05
0.00
Control Group-Saline

Bevacizumab Group

PH Group

PH + Bevacizumab

Figure 2: a. RVP measurements of the experiment groups; b. Fulton Index measurements of the experiment groups. Mean, and SD of
the measurements were provided in the figures. P value to define statistical significance for comparisons of control group - saline vs
bevacizumab group, and PH group vs PH + Bevacizumab group was 0.025. *: control group - saline vs PH group; **: control group saline vs Bevacizumab group; ***: PH group vs PH + Bevacizumab group.

VEGF tissue scores of the experiment groups are shown in
Figure 6. Four different VEGF antibody - stained sections
of small pulmonary arteries are shown in Figures 7a–7d.
In the pathological examination, we did not observe
emphysema in animals in the experiment groups.
4. Discussion
In this experimental study, we investigated the effect of
bevacizumab on PH in hypoxia-induced rat model. One
of the primary issues in this study was the successful
implementation of the hypoxia model. When the normoxia
and hypoxia groups were compared, we observed that the
animals’ weight measurements in the hypoxia groups on
the 5th and 8th days were significantly lower than those
in the normoxia groups. RVP and Fulton Index values,
which are important indicators of PH, were significantly
higher in the hypoxia than the normoxic group. In general,
no significant effect of bevacizumab administration was
observed in the normoxic group in these measurements.
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However, in the hypoxic group, there was a significant
decrease in RVP, Fulton Index, MT, MT%, VEGF score
levels with bevacizumab administration. In our study,
findings such as the increase in right ventricular pressures
that develop in a short time due to hypoxia and right
ventricular hypertrophy are consistent with the previous
study results [7,19,27]. Additionally, we thought that the
weight loss observed in animals with the application of
hypoxia in our study might result from the decrease in
oral intake, dehydration, and increase in basal metabolism
due to respiratory distress secondary to PH and general
condition disorder [15,20,28].
Bevacizumab administration had no statistically
significant effect on serum VEGF levels in either control
or hypoxia groups. However, some publications in the
literature show that serum VEGF levels are higher in
humans with PH diagnosis [29] and animals in which
experimental PH models were established [13,14]
compared to control groups. It was interesting that

DEMİR et al. / Turk J Med Sci

* p: 0.200; ** p: 0.262; *** p: 0.873
120

VEGF pg/ml

100
80
60
40
20
0
Control Group-Saline

Bevacizumab Group

PH Group

PH + Bevacizumab

Figure 3: Serum VEGF levels of the experiment groups. Mean, and SD of the measurements were provided in the figure. P value to
define statistical significance for control group - saline vs bevacizumab group, and PH group vs PH + Bevaciuzmab group was 0.025. *:
control group - saline vs PH group; **: control group - saline vs bevacizumab group; ***: PH group vs. PH + Bevaciuzmab group.

serum VEGF levels were not affected by bevacizumab
administration. We do not have any previously published
data on what could be the underlying mechanism for
this. However, there can be some possible mechanisms
and underlying explanations for this finding. A major
explanation may be the statistical power of the study. In
experimental animal studies, it is a universal rule that the
number of animals per experimental group should be as
low as possible for ethical reasons. This ethical rule affects
the power of the study, so it becomes challenging to reveal
small differences between groups. Again, more than two
comparison groups in experimental studies also make
it difficult to detect the small differences as statistically
significant. In addition, possible experimental errors
related to the ELISA - based method we used in serum
VEGF measurements may also have affected our results.
Thus, it is likely that we may have missed an existing effect
due to the methods used in our study.
Hypoxia-induced and monocrotaline - induced
models, which are widely used to induce PH in animals,
are successful in forming some characteristic pathological
changes of PH, such as nonspecific medial and adventitial
thickening in pulmonary arteries. Nevertheless, it is known
that findings related to chronic, progressive processes
of PH such as angio - obliterative plexiform lesions,
neointima proliferation, and mononuclear cell infiltration
do not develop [27,30,31]. Besides, PH’s pathological and
clinical findings may differ in both the distinct species
of animals and in different strains of the same species
[32,33]. In addition to these differences in animals, PH
can also differ between different human groups and races
[34,35]. Also, it has been observed that PH, which occurs

in hypoxia - induced animal models, is reversible, and
pulmonary artery pressures can return to normal with a
transition from the hypoxic environment to the normoxic
environment [27]. However, PH is generally irreversible in
humans. It has been suggested that the hypoxia - induced
PH model is closer to milder PH levels in humans and
PH secondary to interstitial lung diseases, sleep disorders,
chronic obstructive pulmonary disease, and high altitude
[27]. When all this information is considered together,
we can interpret that although the hypoxia - induced
PH model is the classical and most commonly used PH
animal model; it cannot fully reflect PH’s mechanism and
clinical results in humans. However, we preferred to use
this model in our study because it is one of the best-known
models. These weaknesses of the model mentioned above
should be taken into consideration while evaluating our
study findings.
In this study, the effects of bevacizumab, a selective
VEGF antibody, on PH were investigated. Since chronic
hypoxia is the primary mechanism that triggers VEGF
production, the chronic hypoxia model is frequently
used in studies to reveal the relationship between PH and
VEGF [7,16,29,36,37]. Therefore, we chose to use the same
model in our study. VEGF and its tyrosine kinase receptor
VEGFR - 2 have an essential role in angiogenesis and
endothelial cell protection [38]. It is known that specific
VEGFR - 2 inhibitors [39] and VEGFR - 2 monoclonal
antibodies [40], and VEGFR - 2 phenotypic knockouts
can inhibit neoangiogenesis [38]. Bevacizumab, a VEGF
- A monoclonal antibody, is the first antiangiogenic drug
approved by the FDA [41] which is used in many cancer
types’ treatment schemes, especially colon cancer and non-
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35
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a
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Me d ia l t hickne ss, %

* p: 0.004; ** p: 0.872; *** p: 0.016

25

Bevacizumab Group

PH Group

PH + Bevacizumab

* p: 0.004; ** p: 0.128; *** p: 0.016

b

20
15
10
5
0
Control Group-Saline

Bevacizumab Group

PH Group

PH + Bevacizumab

Figure 4: a. Muscularis mucosa layer thickness (medial thickness: MT) of the experiment groups; b. MT% of the experiment groups.
Mean, and SD of the measurements were provided in the figure. P value to define statistical significance for comparisons of control
group - saline vs bevacizumab group, and ph group vs ph + bevacizumab Group was 0.025. *: control group - saline vs PH group; **:
control group - saline vs bevacizumab group; ***: PH Group vs. PH + bevacizumab group.

small cell lung cancer [42]. Case reports and some studies
show that bevacizumab can cause PH in individuals with
previously normal pulmonary artery pressures by using it
in cancer treatment [43,44]. However, this has not been
confirmed by studies with large case numbers [45]. Drug’s
effect on pulmonary arterial pressures or right ventricular
hypertrophy in individuals already diagnosed with
pulmonary hypertension.
Previous study findings show that proliferative
pulmonary vasculopathy might develop in rats when
SU5416 (a VEGF receptor blocker) and hypoxia are
applied together. However, unlike bevacizumab, SU5416
blocks VEGF receptors, platelet derived growth factor
(PDGF) receptor, c - Kit (stem cell factor receptor), and
RET (tyrosine kinase receptor), not VEGF itself, causes
emphysema as well as pulmonary hypertension [7]. In
contrast to the studies performed with SU5416, we did not
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observe emphysema in animals in the experimental group
in our study.
It is known that the mechanisms of PH caused by the
hypoxia-induced PH model in rodents and the structural
changes in tissues are insufficient to reflect many types
of PH in humans, especially severe PH types. In this
respect, there are problems in generalizing the results of
this study to human PH subtypes. However, in this study,
it is important that the hypoxia - induced PH model
was successfully applied, and significant improvements
were observed in many parameters related to PH with
bevacizumab administration in hypoxemic rats.
In conclusion, significant decreases in RV pressures,
Fulton İndex, medial thickness, medial thickness% scores
and tissue VEGF scores detected with bevacizumab
application in the hypoxia - induced PH model shows
that bevacizumab can affect the pathogenesis and clinical
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Figure 5: Hematoxylin & Eosin staining of small pulmonary arteries (at × 40 magnification) a. Normal pulmonary artery; b.
Pulmonary artery with moderate thickening of the muscular layer; c. Pulmonary artery with significant thickening of the muscular
layer; d. Pulmonary artery with a double muscular layer.

* p: 0.004; ** p: 1; *** p: 0.004
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Figure 6: VEGF tissue scores of the experiment groups. Mean, and SD of the measurements are provided in the
figure. P value to define statistical significance for comparisons of control group - saline vs bevacizumab group, and
PH Group vs PH + bevacizumab group was 0.025. *: control group - saline vs. PH group; **: control group - saline vs
bevacizumab group; ***: PH group vs PH + bevacizumab group.

Figure 7: VEGF antibody staining of small pulmonary arteries (with 1 / 200 dilution and × 40 magnification) a. Partial and mild
intensity staining of a normal pulmonary artery; b. Moderate intensity and 90% staining of a pulmonary artery with moderate
muscular hypertrophy; c. Strong intensity and 100% staining of a pulmonary artery with muscular hypertrophy; d. Strong intensity
and 100% staining of a pulmonary artery with severe muscular hypertrophy.
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findings in at least some types of PH. It is known that the
results of this study cannot completely reflect the human
condition due to reasons such as hypoxia - induced animal
models are insufficient to reflect many PH subtypes in
humans, and bevacizumab was originally produced as
a human VEGF antibody. Besides, the role of VEGF in
the pathogenesis of PH and the clinical effects of VEGF
antibodies and inhibitors in individuals with PH are
still unknown. We think that, our study shed a light on
the possible effects of a molecule – bevacizumab - used
extensively in cancer treatment on the pathogenesis and
treatment of PH.
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